Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-03-30

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

Despite declining incidence rates, gastric cancer remains the second most common tumor type and second cause of cancer-related death worldwide. Gastric cancer occurs nearly five times more frequently in Japan than in the West. While early diagnosis and encouraging survival rates are common in Japan, the disease confers greater mortality in the West, thus representing a significant health burden.

Scope

Current diagnosis and treatment of gastric cancer, including treatment regimens by stage and ongoing controversies

Issues and unmet needs in current treatment, screening and geographical treatment variations

Examination of the gastric cancer pipeline and market opportunities for drug developers

Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders in the US, Europe and Japan

Report Highlights
Gastric cancer has never been the most attractive indication for drug developers, which is evidenced by the current lack of approved agents for its treatment. This situation has changed over the past few years and numerous targeted therapies are now in Phase II trials, which are expected to eventually revolutionize treatment of gastric cancer.

The incorporation of neoadjuvant therapy into treatment guidelines is likely to be the next major change to occur in the gastric cancer market. Positive results from the recent MAGIC trial showed the feasibility of neoadjuvant therapy and its advantages over adjuvant therapy, the concept of which is greatly anticipated by key opinion leaders.

At present, the ECF regimen constitutes standard first-line chemotherapy for advanced gastric cancer. Several large-scale randomized clinical trials are currently assessing the newer cytotoxics for this treatment setting and despite seemingly positive results, only the REAL-2 study is expected to cause a great impact.

Reasons to Purchase

Identify the limitations of current therapy available to gastric cancer patients and the potential of future therapy

Understand current epidemiological trends in gastric cancer and ongoing treatment controversies

Assess the opportunities for innovative targeted therapies in the gastric cancer market, particularly in metastatic disease

ABOUT DATAMONITOR HEALTHCARE - page 2
- About the Oncology pharmaceutical analysis team - page 2
CHAPTER 1 EXECUTIVE SUMMARY - page 3
- Scope of analysis - page 3
- Datamonitor insight into the gastric cancer market - page 3
  - Datamonitor estimates that approximately 196,000 new cases of gastric cancer will be diagnosed in the seven major markets in 2006, with 56% occurring in Japan alone. Overall incidence of gastric cancer continues to decrease for a number of reasons and a shift has occurred in the frequency of distal gastric tumors towards increased diagnosis of proximal tumors. - page 4
  - The incorporation of neoadjuvant therapy into treatment guidelines is likely to be the next major change to occur in the gastric cancer market. Positive results from the recent MAGIC trial showed the feasibility of the ECF (epirubicin, cisplatin and 5-fluorouracil) regimen in the neoadjuvant setting for gastric cancer and its advantages over adjuvant therapy, the introduction of which is greatly anticipated by key opinion leaders. - page 7
  - At present, the ECF regimen constitutes standard first-line chemotherapy for advanced gastric cancer. Several large-scale randomized clinical trials are currently assessing the newer cytotoxics for this treatment setting but despite seemingly positive results, only the REAL-2 study, which aims to update the ECF regimen with oxaliplatin and/or capecitabine, is expected to have a significant impact. - page 10
  - Gastric cancer has never been the most attractive indication for drug developers, as shown by the lack of approved agents for its treatment. This situation has changed over the past few years and numerous targeted therapies are now in Phase II trials, which are expected to eventually revolutionize the treatment of gastric cancer. - page 13
CHAPTER 2 DISEASE OVERVIEW - page 22
- Introduction - page 22
  - Disease overview - page 22
    - Declining incidence, but still a major health burden - page 22
  - The stomach - page 23
- Gastric cancer - page 24
  - Definition - page 24
  - Pathology & classification - page 24
    - Adenocarcinomas account for the majority of gastric tumors - page 24
    - Focus will be on adenocarcinomas due to high incidence, and gastrointestinal stromal tumors due to its unique properties - page 26
    - Several classification systems exist, based on pathology and histology - page 27
  - Epidemiology - page 28
    - Despite a worldwide decline in incidence, gastric cancer remains a major health burden - page 28
    - Much higher incidence in Asia, Eastern Europe and South America... - page 31
    - ...but mortality is a greater concern in the US, Western Europe and Australasia - page 32
    - Some types of gastric cancer now more common than others - page 32
    - Misclassification means GIST is more common than previously thought - page 34
  - Risk factors - page 34
    - Genetic and environmental factors - page 35
    - Precursor conditions - page 38
  - Symptoms - page 41
    - Non-specific nature of symptoms results in frequent late diagnosis of gastric cancer - page 41
  - Screening - page 42
    - Screening programs are more effective in high-incidence areas with large high-risk patient populations - page 42
  - Diagnosis - page 44
    - Endoscopy and biopsy are the most accurate methods of diagnosing gastric cancer - page 44
    - Serological tumor markers of little value - page 45
  - Staging - page 45
    - The TNM staging system is in more widespread use - page 45
    - The more detailed Japanese staging system is used only in Japan - page 48
  - Survival - page 51
    - Vast differences in five-year survival rates between the US and Japan - page 51
  - Prognosis - page 54
    - Type and site of primary gastric tumor - page 54
    - Extent of invasion through the stomach wall and nodal involvement - page 54
    - Tumor size - page 55
    - Other histological prognostic indicators - page 55
    - Genetic and molecular abnormalities - page 55
  - Prevention - page 56
    - Eradication of H. pylori not a viable option - page 56
    - Diet may have a significant preventative role - page 56
    - Other compounds may have a protective role - page 57
CHAPTER 3 CURRENT TREATMENT OPTIONS - page 58
- Introduction - page 58
- Treatment overview - page 58
  - Treatment guidelines for the US - page 58
  - Treatment guidelines for Europe - page 62
  - Treatment guidelines for Japan - page 62
- Stage-specific treatment - page 63
  - Treatment of stage 0 gastric cancer - page 64
    - Surgery alone is associated with high five-year survival rates - page 64
  - Treatment of stage I gastric cancer - page 64
    - Subtotal gastrectomy may be sufficient for stage IA gastric cancer - page 64
    - Stage IB gastric cancer requires additional lymphadenectomy and/or adjuvant chemoradiotherapy - page 65
    - In Japan, only surgical procedures are employed for stage I patients - page 65
  - Treatment of stage II gastric cancer - page 66
    - Stage II treatment includes both surgery and adjuvant chemoradiotherapy - page 66
    - Adjuvant chemotherapy is recommended in Japan, although no standard regimen exists - page 66
  - Treatment of stage III gastric cancer - page 66
    - All stage III gastric cancer patients should undergo surgery and adjuvant chemoradiotherapy - page 66
    - Neoadjuvant therapy should be considered for stage IIIB patients and those with unresectable disease - page 67
    - Neoadjuvant chemotherapy, surgery and adjuvant chemotherapy and/or radiotherapy should all be considered in Japan - page 68
  - Treatment of stage IV gastric cancer - page 68
    - Patients without distant metastases should enter clinical trials if surgery is not a viable option - page 68
    - All treatment options serve only palliative purposes, although chemotherapy may result in durable remissions - page 68
    - As in the West, all stage IV gastric cancer treatment options in Japan serve only palliative purposes - page 69
- Treatment of GIST - page 69
  - Treatment guidelines for the US - page 69
    - The aggressiveness of GIST has traditionally been underestimated - page 69
    - Heavy reliance upon surgery, however this does not regularly provide a cure - page 72
    - Novartis's Gleevec (imatinib) can be administered at all stages of GIST with a likely subsequent tumor response - page 72
    - Progressive GIST patients should be enrolled into clinical trials or receive Gleevec - page 73
- Treatment of other gastric tumor types - page 74
  - Gastric lymphoma - page 74
    - Antibiotic therapy against H. pylori and radiotherapy offers the best chance of a cure - page 74
  - Gastric leiomyosarcoma - page 75
    - Surgery remains the cornerstone of therapy, however other treatment options are lacking - page 75
  - Gastric carcinoid tumors - page 75
    - Surgery often provides a cure, but management of 'carcinoid syndrome' is also necessary - page 75
CHAPTER 4 CURRENT TREATMENT REGIMENS AND CONTROVERSIES - page 77
- Current treatment regimens and controversies - page 77
  - Surgery - page 77
    - Aim is to remove involved stomach but preserve continuity - page 77
    - Depending on extent of primary tumor, subtotal gastrectomy may be sufficient - page 77
    - Japanese surgeons become more experienced at limited resections - page 77
    - Reconstruction surgery is often necessary, depending on site of primary tumor - page 78
    - Advanced disease cases may require removal of adjacent organs - page 78
    - Significant complications can arise as a result of gastrectomy - page 78
    - Controversies arise over the extent of resection and applicability of limited resection - page 79
  - Lymphadenectomy - page 80
    - Lymphadenectomy should be performed, although debate continues over the appropriate extent of resection - page 80
    - D1 versus D2 lymphadenectomy: increased survival but greater morbidity? - page 82
    - Modified D2 lymphadenectomies may reduce the incidence of post-surgical morbidity - page 83
  - Neoadjuvant therapy - page 84
    - Neoadjuvant therapy has a number of advantages over treatment in the adjuvant setting - page 84
    - Phase II clinical trials have demonstrated the feasibility of neoadjuvant chemotherapy - page 85
    - Early Phase III trials demonstrated feasibility of neoadjuvant therapy, although no survival benefit was shown - page 86
    - The Phase III MAGIC trial has shown that neoadjuvant chemotherapy confers a significant survival benefit - page 88
    - Results from other ongoing Phase III clinical trials are expected to determine applicability for neoadjuvant therapy to current regimens - page 90
    - Neoadjuvant radiotherapy has not produced remarkable results and further study is not taking place - page 91
    - Neoadjuvant chemoradiotherapy may have potential although there are few studies exploring this option - page 92
  - Adjuvant therapy - page 93
    - Despite finding a place in standard treatment, many controversies over the use of adjuvant therapy still exist - page 93
    - A lack of convincing clinical trial data means adjuvant chemotherapy is not recommended as the standard-of-care - page 93
    - Potential for adjuvant chemotherapy may lie in newer cytotoxic agents - page 95
    - Radiotherapy is unlikely to be administered in the adjuvant setting unless it is alongside chemotherapy - page 95
    - Despite criticism, the adjuvant chemoradiotherapy used in the INT-0116 trial has become the standard of care in the US - page 96
    - The ongoing Phase III CALGB-80101 chemoradiotherapy trial will help to substantiate INT-0116 study results - page 98
    - East versus West, D2 lymphadenectomy versus adjuvant systemic therapy, does one negate the need for the other? - page 99
  - First-line chemotherapy for advanced disease - page 101
    - Chemotherapy should be offered to those metastatic patients with a good performance status - page 101
    - Single-agent cytotoxics are not widely administered due to minimal efficacy - page 101
    - The FAM regimen (5-fluorouracil, doxorubicin and mitomycin) was the original standard of care for gastric cancer - page 101
    - In the 1990s, FAMTX replaced FAM as the regimen of choice - page 102
    - The ECF regimen (epirubicin, cisplatin, 5-fluorouracil) is now the current standard for the first-line treatment of advanced gastric cancer - page 103
    - Ongoing clinical trials for pipeline compounds signal a potential shift in the standard of care for metastatic gastric cancer - page 103
    - The REAL-2 trial is aiming to update the ECF regimen by using oxaliplatin and capecitabine - page 104
    - Marketing authorization of Taxotere represents the first FDA approval for gastric cancer since 1970 - page 106
    - Irinotecan has yet to show survival benefits in large-scale randomized Phase III clinical trials - page 108
    - S-1 is the cytotoxic of choice in Japan: genetic differences make it more tolerable in Asian patients - page 109
    - The future of chemotherapy - page 111
  - Second-line chemotherapy - page 111
    - Lack of a standard second-line chemotherapy regimen could change with upcoming results of an ongoing Phase III clinical trial - page 111
  - Intraperitoneal chemotherapy - page 112
    - Intraperitoneal chemotherapy can result in decreased locoregional recurrence rates - page 112
    - Adjuvant intraperitoneal chemotherapy following neoadjuvant therapy and surgery is effective on a number of different levels - page 112
    - Trials investigating adjuvant intraperitoneal chemotherapy have resulted in widely varying survival benefits - page 113
    - Ongoing clinical trials aim to further develop the role of intraperitoneal chemotherapy in the treatment of gastric cancer - page 114
  - Intraoperative radiotherapy - page 115
    - Mixed clinical trial results mean intraoperative radiotherapy remains an experimental treatment modality - page 115
  - Gleevec therapy for GIST - page 117
    - Novartis's Gleevec (imatinib) induces lengthy tumor responses at a standard dose of 400mg per day - page 117
    - Higher doses of Gleevec may be beneficial in some patients, although further clinical studies are required - page 118
    - Gleevec treatment remains experimental in the neoadjuvant and adjuvant settings - page 119
CHAPTER 5 UNMET NEEDS - page 121
- Introduction - page 121
- Unmet needs - page 121
  - Factors to positively impact prognosis - page 121
    - The lack of effective systemic therapy and heavy reliance upon surgery indicates an urgent need for earlier diagnosis in the West - page 121
    - Improving patient lifestyle factors could prevent or delay the onset of gastric cancer - page 123
    - Better use must be made of diagnostic imaging techniques - page 124
  - Improved treatment options are needed across the board - page 124
    - Surgery in the West needs to approach the same level of effectiveness as in Japan - page 124
    - New effective therapies are required for control of distant metastatic disease - page 125
    - More large-scale, randomized clinical trials are necessary to define optimal treatment strategies at all stages of gastric cancer - page 126
    - The unresponsiveness of gastric cancer reduces its attractiveness to drug developers - page 128
- Summary of unmet needs - page 128
CHAPTER 6 PIPELINE ANALYSIS - page 130
- The gastric cancer pipeline - page 130
  - The future treatment of gastric cancer will depend on successfully incorporating innovative targeted therapies - page 130
- Review of key pipeline compounds for gastric cancer - page 132
  - Eli Lilly's Alimta (pemetrexed) - page 133
    - Alimta's price may hamper its uptake in light of cheaper generic alternatives - page 133
  - Genentech/Roche's Avastin (bevacizumab) - page 134
    - Drug-of-the-moment Avastin shows some efficacy although the incidence of thromboembolic events and bleeding remains a major concern - page 134
  - ImClone/Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) - page 137
    - Lack of clinical trial data makes Erbitux's potential difficult to judge, although its cost may represent a major deterrent - page 137
  - Novartis's Gleevec (imatinib) - page 138
    - Despite a theoretical rationale for the use of Gleevec in gastric cancer, the lack of clinical trial data in humans make its potential difficult to judge - page 138
  - Genentech/Roche's Herceptin (trastuzumab) - page 140
    - Phase III trial results eagerly anticipated to assess the full viability of Herceptin in HER2-positive gastric cancer - page 140
  - Aphton Corporation's Insegia (G17DT) - page 142
    - Skepticism over cancer vaccines and Insegia's failures in pancreatic cancer signal a bleak future in gastric cancer - page 142
  - AstraZeneca's Iressa (gefitinib) - page 144
    - AstraZeneca's non-involvement means that Iressa's already troubled existence looks bleak for gastric cancer - page 144
  - Onyx Pharmaceuticals/Bayer's Nexavar (sorafenib) - page 145
    - First-to-market status in renal cell carcinoma could place Nexavar at a slight advantage over Sutent - page 145
  - Pfizer's Sutent (sunitinib) - page 146
    - Sutent appears to be lagging slightly behind Nexavar, which could have a negative affect on its future position in the gastric cancer market - page 146
  - OSI Pharmaceuticals/Genentech/Roche's Tarceva (erlotinib) - page 148
    - Tarceva may again have the upper hand over Iressa, this time in the gastric cancer market - page 148
  - GlaxoSmithKline's Tykerb (lapatinib) - page 149
    - Theoretical advantages exist, although the lack of definitive data in gastric cancer makes it difficult to judge Tykerb's full potential - page 149
  - Ortho Biotech/Millennium Pharmaceuticals' Velcade (bortezomib) - page 151
    - While single-agent activity is low, administration of Velcade alongside chemotherapy demonstrates efficacy - page 151
- The GIST pipeline - page 152
  - Low incidence of GIST has translated into a relatively sparse pipeline - page 152
  - Pfizer's Sutent (sunitinib) - page 153
    - Sutent represents an important breakthrough in the treatment of Gleevec-refractory GIST, where no alternative treatment options exist - page 153
  - Other GIST pipeline compounds - page 155
    - Significant superiority needs to be shown over Gleevec and Sutent in order to make an impact - page 155
- Strategies for commercialization in gastric cancer - page 155
  - Increasing attractiveness of gastric cancer - page 155
    - The next few years will start to provide definitive answers on the potential of targeted therapies in gastric cancer - page 155
  - Which geographical location is best for development given the differences in incidence of gastric cancer? - page 156
    - Differences in gastric cancer on a molecular level between Asia and the West mean initial R&D efforts in Japan do not correlate with western markets - page 156
  - Optimal stage of development: minimal residual disease or metastatic and/or unresectable disease? - page 157
    - A double-pronged approach is necessary in gastric cancer due to high unmet needs across the board - page 157
CHAPTER 7 OPINION LEADER INTERVIEW TRANSCRIPTS - page 159
- Contributing experts - page 159
- Opinion leader interview transcripts - page 159
  - Doctor A William Blackstock, Wake Forest University School of Medicine, Winston-Salem, North Carolina, US - page 159
  - Doctor Thomas Cartwright, Ocala Oncology Center, Ocala, Florida, US - page 174
  - Doctor Edwin Jansen, Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands - page 185
  - Doctor Mitsuru Sasako, Gastric Surgery Division, Department of Surgery, National Cancer Center Hospital, Tokyo, Japan - page 194
APPENDIX - page 203
- Bibliography - page 203
- List of tables - page 223
- List of figures - page 227
- About Datamonitor - page 228
  - About Datamonitor Healthcare - page 228
  - About the Oncology analysis team - page 229
- Disclaimer - page 230

List of Tables
Table 1: Estimated incidence of gastric cancer in the seven major pharmaceutical markets, 2000-14 - page 5
Table 2: WHO classification system for gastric adenocarcinoma - page 25
Table 3: Lauren classification system for gastric adenocarcinoma - page 25
Table 4: Histological grading system for gastric adenocarcinomas - page 26
Table 5: Proportion of different pathologies of gastric tumor - page 26
Table 6: Gross anatomy classification for gastric tumors - page 27
Table 7: Borrmann classification system for gastric tumors - page 27
Table 8: Japanese Society for Gastroenterological Endoscopy classification system for gastric tumors - page 28
Table 9: Crude incidence rates of gastric cancer by gender per 100,000 in the seven major pharmaceutical markets - page 28
Table 10: Estimated incidence of gastric cancer in the seven major pharmaceutical markets, 2000-14 - page 29
Table 11: Incidence and mortality from gastric cancer in 2000 and 2014 across the seven major pharmaceutical markets - page 30
Table 12: Risk factors for the development of gastric cancer - page 35
Table 13: TNM classification system for gastric cancer - page 46
Table 14: TNM staging system for gastric cancer - page 47
Table 15: R classification system for gastric cancer - page 48
Table 16: Japanese Surgical Classification System for gastric cancer (1 of 2) - page 48
Table 17: Japanese Surgical Classification System for gastric cancer (2 of 2) - page 49
Table 18: Japanese Surgical Staging System for gastric cancer - page 49
Table 19: Lymph node groups (1-3) by location of gastric tumor - page 50
Table 20: Approximate percentage of gastric cancer patients diagnosed at each stage - page 52
Table 21: Five-year survival rates by stage for gastric cancer in the US and Japan - page 52
Table 22: Karnofsky performance status scale - page 61
Table 23: ECOG performance status scale - page 61
Table 24: Overview of gastric cancer treatment by stage in the US - page 63
Table 25: Overview of gastric cancer treatment by stage in Japan - page 64
Table 26: Phase II clinical trial results of neoadjuvant chemotherapy for gastric cancer - page 86
Table 27: Results from the Phase III clinical trial reported by Kang et al. - page 87
Table 28: Post-operative staging of patients in the Kang et al. trial - page 87
Table 29: Post-operative results from the MAGIC trial - page 88
Table 30: Disease staging following neoadjuvant therapy and/or surgery in the MAGIC trial - page 88
Table 31: Recurrence rates in the MAGIC trial - page 89
Table 32: Rates of survival in the MAGIC trial - page 89
Table 33: Clinical trials investigating neoadjuvant chemotherapy for gastric cancer - page 90
Table 34: Phase II clinical trial results of neoadjuvant chemoradiotherapy for gastric cancer - page 92
Table 35: Clinical trials investigating adjuvant chemotherapy for gastric cancer - page 95
Table 36: Five-year follow-up results from the INT-0116 trial - page 97
Table 37: Interim toxicity results from the CALGB-80101 trial - page 99
Table 38: Results from the Kim et al. trial (2005) - page 100
Table 39: Results from the Kim et al. trial (1993) - page 102
Table 40: Interim analysis results from the REAL-2 trial - page 105
Table 41: Grade 3/4 toxicities (% of patients) at interim analysis of the REAL-2 trial - page 105
Table 42: Results from the TAX 325 trial - page 106
Table 43: Grade 3/4 toxicity in the TAX 325 trial (% of patients) - page 107
Table 44: Phase II clinical trial results for single-agent S-1 - page 110
Table 45: Clinical trial results for intraperitoneal chemotherapy following neoadjuvant therapy and surgery - page 113
Table 46: Survival data from the randomized trials meta-analyzed by Xu et al. (2004) - page 114
Table 47: Results from randomized clinical trials investigating intraoperative radiotherapy for gastric cancer - page 116
Table 48: Results from the pivotal Phase II trial investigating Gleevec in advanced GIST at 15 months follow-up - page 118
Table 49: Ongoing clinical trials investigating neoadjuvant and/or adjuvant Gleevec for treatment of GIST - page 120
Table 50: Survival by depth of tumor invasion and nodal involvement of gastric cancer - page 122
Table 51: Late-phase gastric cancer pipeline, 2006 - page 130
Table 52: Phase II gastric cancer pipeline, 2006 - page 131
Table 53: Early-phase gastric cancer pipeline, 2006 - page 132
Table 54: Clinical trials investigating Avastin in gastric cancer - page 135
Table 55: Clinical trials investigating Erbitux for gastric cancer - page 137
Table 56: Clinical trials investigating Gleevec in gastric cancer - page 139
Table 57: Clinical trials investigating Herceptin in gastric cancer - page 140
Table 58: Clinical trials investigating Velcade in gastric cancer - page 151
Table 59: GIST pipeline, 2006 - page 153

List of Figures
Figure 1: Estimated incidence of gastric cancer in the seven major pharmaceutical markets, 2000-14 - page 5
Figure 2: Anatomy of the stomach - page 23
Figure 3: Estimated incidence of gastric cancer in the seven major pharmaceutical markets, 2000-14 - page 29
Figure 4: Incidence and mortality from gastric cancer in 2000 and 2014 across the seven major pharmaceutical markets - page 30
Figure 5: Gastric cancer treatment guidelines after diagnosis in the US - page 59
Figure 6: Gastric cancer treatment guidelines following surgery in the US - page 59
Figure 7: Gastric cancer treatment guidelines following first-line systemic therapy in the US - page 60
Figure 8: Gastric cancer treatment guidelines for salvage therapy in the US - page 60
Figure 9: Gastric cancer treatment guidelines in Europe - page 62
Figure 10: Gastric cancer treatment guidelines in Japan - page 63
Figure 11: GIST treatment guidelines after diagnosis in the US - page 70
Figure 12: Potentially resectable GIST treatment guidelines in the US - page 70
Figure 13: Unresectable GIST treatment guidelines in the US - page 71
Figure 14: Resectable GIST treatment guidelines after surgery in the US - page 71
Figure 15: Progressive GIST treatment guidelines in the US - page 72
Figure 16: Lymph nodes stations in the gastric region - page 81
Figure 17: Summary of unmet needs in the gastric cancer market - page 129

Other users found this report page using the following search terms: gastric cancer gastric cancer stomach avastin tumors chemo chemotherapy treatment costs targeted

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type

Credit Card Details

Invoice Details

Table of Contents